{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:19:16Z","timestamp":1790299156173,"version":"4.1.0"},"reference-count":32,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"2","content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introducci\u00f3n. Existen evidencias sobre el uso indiscriminado de antibi\u00f3ticos en el tratamiento de diversas enfermedades.Objetivo. Determinar los patrones de prescripci\u00f3n y de indicaciones de uso de las fluoroquinolonas en un grupo de pacientes ambulatorios en Colombia.Materiales y m\u00e9todos. Se llev\u00f3 a cabo un estudio descriptivo farmacoepidemiol\u00f3gico del tipo de prescripci\u00f3n e indicaciones de uso a partir de una base de datos poblacionales que inclu\u00eda pacientes con prescripciones ambulatorias de fluoroquinolonas entre mayo y octubre de 2018. Se recab\u00f3 la informaci\u00f3n sobre las variables sociodemogr\u00e1ficas, farmacol\u00f3gicas y cl\u00ednicas (diagn\u00f3stico seg\u00fan la Clasificaci\u00f3n Internacional de Enfermedades, versi\u00f3n 10) y se estableci\u00f3 la proporci\u00f3n del uso de fluoroquinolonas en indicaciones aprobadas y no aprobadas por las agencias reguladoras.Resultados. Se identificaron 23.373 pacientes que hab\u00edan recibido fluoroquinolonas; su edad media era de 47,9 \u00b1 18,1 a\u00f1os y 15.767 eran mujeres (67,5 %). La ciprofloxacina fue el medicamento m\u00e1s prescrito (n=19.328; 82,7 %), seguida de la norfloxacina (n=3.076; 13,2 %), la levofloxacina (n=573; 2,5 %) y la moxifloxacina (n=394; 1,7 %). Las principales indicaciones fueron la infecci\u00f3n de las v\u00edas urinarias en sitio no especificado (n=10.777; 46,1 %), la diarrea y la gastroenteritis de presunto origen infeccioso (n=3.077, 13,2 %) y la cistitis aguda (n=956; 4,2 %). El 76 % (n=17.759) de las prescripciones correspond\u00eda a indicaciones aprobadas y el resto a usos no aprobados, como la rinofaringits o las infecciones de tejidos blandos. El ser hombre (odds ratio, OR=1,26; IC95%: 1,18-1,34) y tener menos de 35 a\u00f1os (OR=1,92; IC95%:1,48-1,50) se asociaron con una mayor probabilidad de uso de fluoroquinolonas en indicaciones no aprobadas.Conclusi\u00f3n. Las fluoroquinolonas, en particular la ciprofloxacina, se est\u00e1n prescribiendo especialmente a mujeres con infecciones de las v\u00edas urinarias, pero hasta la cuarta parte de los pacientes las recibieron para usos no aprobados por las agencias reguladoras.<\/jats:p>","DOI":"10.7705\/biomedica.5103","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T15:00:07Z","timestamp":1594738807000},"page":"382-390","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Prescripci\u00f3n e indicaciones de uso de fluoroquinolonas en un grupo de pacientes ambulatorios de Colombia"],"prefix":"10.7705","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0986","authenticated-orcid":false,"given":"Manuel Enrique","family":"Machado-Duque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Mercado-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Camila","family":"Bernal-Chica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Uribe-V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Enrique","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4444","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"99166","unstructured":"CDC. Antibiotic use in the United States, 2017: Progress and opportunities. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. Fecha de consulta: 20 de enero de 2019. Disponible en: https:\/\/www.cdc.gov\/antibiotic-use\/stewardship-report\/pdf\/stewardshipreport.pdf"},{"key":"99167","unstructured":"Organizaci\u00f3n Mundial de la Salud. Promoci\u00f3n del uso racional de medicamentos: componentes centrales. Perspectivas pol\u00edticas sobre medicamentos de la OMS. 2002. Fecha de consulta: 31 de mayo de 2019 Disponible en: https:\/\/apps.who.int\/medicinedocs\/pdf\/s4874s\/s4874s.pdf"},{"key":"99168","doi-asserted-by":"crossref","unstructured":"Kabbani S, Hersh AL, Shapiro DJ, Fleming-Dutra KE, Pavia AT, Hicks LA. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis. 2018;67:134-6. https:\/\/doi.org\/10.1093\/cid\/ciy035","DOI":"10.1093\/cid\/ciy035"},{"key":"99169","doi-asserted-by":"crossref","unstructured":"Hersh AL, Fleming-Dutra KE, Shapiro DJ, Hyun DY, Hicks LA. Frequency of first-line antibiotic selection among US ambulatory care visits for otitis media, sinusitis, and pharyngitis. JAMA Intern Med. 2016;176:1870-2. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6625","DOI":"10.1001\/jamainternmed.2016.6625"},{"key":"99170","doi-asserted-by":"crossref","unstructured":"Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: A systematic review and meta-analysis of observational studies. BMC Infect Dis. 2015;15:545. https:\/\/doi.org\/10.1186\/s12879-015-1282-4","DOI":"10.1186\/s12879-015-1282-4"},{"key":"99171","doi-asserted-by":"crossref","unstructured":"Kabbara WK, Ramadan WH, Rahbany P, Al-Natour S. Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia. Ther Clin Risk Manag. 2015;11:639-47. https:\/\/doi.org\/10.2147\/TCRM.S81280","DOI":"10.2147\/TCRM.S81280"},{"key":"99172","unstructured":"World Health Organization. Antimicrobial resistance: Global report on surveillance. World Health Organization; 2014. Fecha de consulta: 20 de enero de 2019. Disponible en: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112642\/9789241564748_eng.pdf;jsessionid=5A9FF7C6F7F6C574BFF16F0F8EAB7FA7?sequence=1"},{"key":"99173","unstructured":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet. 2018;392:821-34."},{"key":"99174","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"99175","unstructured":"World Health Organization. Critically important antimicrobials for human medicine: Ranking of antimicrobial agents for risk management of antimicrobial resistance due to non-human use. World Health Organization; 2017. Fecha de consulta: 20 de enero de 2019. Disponible en: http:\/\/apps.who.int\/medicinedocs\/documents\/s22251en\/s22251en.pdf"},{"key":"99176","unstructured":"World Health Organization. Monitoring and evaluation of the global action plan on antimicrobial resistance (AMR): Regional expert consultation on monitoring and evaluation of AMR interventions. Washington, D.C.: World Health Organization; 2017. Fecha de consulta: 20 de enero de 2019. Disponible en: http:\/\/www.fao.org\/3\/a-i7711e.pdf"},{"key":"99177","doi-asserted-by":"crossref","unstructured":"Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH, Jr., et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308-16. https:\/\/doi.org\/10.1093\/cid\/civ076","DOI":"10.1093\/cid\/civ076"},{"key":"99178","doi-asserted-by":"crossref","unstructured":"Machado-Alba JE, Gonz\u00e1lez-Santos DM. Dispensaci\u00f3n de antibi\u00f3ticos de uso ambulatorio en una poblaci\u00f3n colombiana. Revista de Salud P\u00fablica. 2009;11:734-44.","DOI":"10.1590\/S0124-00642009000500006"},{"key":"99179","doi-asserted-by":"crossref","unstructured":"L\u00f3pez JJ, Garay AM. Estudio de utilizaci\u00f3n de antibi\u00f3ticos en el servicio de consulta externa de un hospital p\u00fablico en Bogot\u00e1, DC. Revista Colombiana de Ciencias Qu\u00edmicas y Farmac\u00e9uticas. 2016;45:35-47. https:\/\/doi.org\/10.15446\/rcciquifa.v45n1.58014","DOI":"10.15446\/rcciquifa.v45n1.58014"},{"key":"99180","doi-asserted-by":"crossref","unstructured":"Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22:438-45. https:\/\/doi.org\/10.1016\/j.tim.2014.04.007","DOI":"10.1016\/j.tim.2014.04.007"},{"key":"99181","unstructured":"Peters S. FDA issues new fluoroquinolone safety warnings and prescribing restrictions. S D Med. 2016;69:418-21."},{"key":"99182","unstructured":"European Association of Urology. Guidelines on urological infections 2015. Fecha de consulta: 20 de enero de 2019. Disponible en: https:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR2.pdf"},{"key":"99183","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics United Kingdom 2018. Fecha de consulta: 20 de enero de 2019. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/disabling-potentially-permanent-side-effects-lead-suspensionrestrictions-quinolone-fluoroquinolone_en.pdf"},{"key":"99184","doi-asserted-by":"crossref","unstructured":"Raff AB, Kroshinsky D. Cellulitis: A review. JAMA. 2016;316:325-37. https:\/\/doi.org\/10.1001\/jama.2016.8825","DOI":"10.1001\/jama.2016.8825"},{"key":"99185","doi-asserted-by":"crossref","unstructured":"Sandoval-Paredes J, Sandoval-Paz C. Uso de f\u00e1rmacos durante el embarazo. Horizonte M\u00e9dico. 2018;18:71-9. https:\/\/doi.org\/10.24265\/horizmed.2018.v18n2.11","DOI":"10.24265\/horizmed.2018.v18n2.11"},{"key":"99186","doi-asserted-by":"crossref","unstructured":"Bar-Oz B, Moretti ME, Boskovic R, O\u2019Brien L, Koren G. The safety of quinolones--a metaanalysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143:75-8. https:\/\/doi.org\/10.1016\/j.ejogrb.2008.12.007","DOI":"10.1016\/j.ejogrb.2008.12.007"},{"key":"99187","unstructured":"American Pharmacists Association. Drug Information Handbook. 27th edition. Washington, D.C.: Lexicomp; 2018-2019. p. 503-8."},{"key":"99188","doi-asserted-by":"crossref","unstructured":"Almalki ZS, Alahmari AK, Guo JJ, Cavanaugh TM. Off-label use of oral fluoroquinolone antibiotics in outpatient settings in the United States, 2006 to 2012. Pharmacoepidemiol Drug Saf. 2016;25:1042-51. https:\/\/doi.org\/10.1002\/pds.4021","DOI":"10.1002\/pds.4021"},{"key":"99189","doi-asserted-by":"crossref","unstructured":"Ray MJ, Tallman GB, Bearden DT, Elman MR, McGregor JC. Antibiotic prescribing without documented indication in ambulatory care clinics: National cross sectional study. BMJ. 2019;367:l6461. https:\/\/doi.org\/10.1136\/bmj.l6461","DOI":"10.1136\/bmj.l6461"},{"key":"99190","doi-asserted-by":"crossref","unstructured":"Suzuki H, Perencevich EN, Alexander B, Beck BE, Goto M, Lund BC, et al. Inpatient fluoroquinolone stewardship improves the quantity and quality of fluoroquinolone-prescribing at hospital discharge: A retrospective analysis among 122 Veterans Health Administration Hospitals. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz967","DOI":"10.1093\/cid\/ciz967"},{"key":"99191","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. Decreto N\u00famero 780 de 2016 Colombia 2016. Fecha de consulta: 20 de enero de 2019. Disponible en: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/DE\/DIJ\/decreto-780-unico-modificado-2016.pdf"},{"key":"99192","doi-asserted-by":"crossref","unstructured":"Machado-Alba JE, Machado-Duque ME, Alzate-Carvajal V. Drugs prescribed by medical students: A suitable practice? Public Health. 2015;129:579-81. https:\/\/doi.org\/10.1016\/j.puhe.2015.01.027","DOI":"10.1016\/j.puhe.2015.01.027"},{"key":"99193","unstructured":"Vacca CP, Ni\u00f1o CY, Reveiz L. Restriction of antibiotic sales in pharmacies in Bogot\u00e1, Colombia: A descriptive study. Rev Panam Salud P\u00fablica. 2011;30:586-91."},{"key":"99194","doi-asserted-by":"crossref","unstructured":"Sim\u00f3 S, Fraile D, S\u00e1nchez A, Garc\u00eda-Algar O. Dispensing of over-the-counter drugs in pharmacies. An Pediatr (Barc). 2013;79:10-4. https:\/\/doi.org\/10.1016\/j.anpedi.2012.10.015","DOI":"10.1016\/j.anpedi.2012.10.015"},{"key":"99195","doi-asserted-by":"crossref","unstructured":"Mont\u00fafar FE, Var\u00f3n FA, Giraldo LF, S\u00e1enz \u00d3A, Rodr\u00edguez A, Alarc\u00f3n AM, et al. Recomendaciones para el diagn\u00f3stico, tratamiento y prevenci\u00f3n de la neumon\u00eda adquirida en la comunidad en adultos inmunocompetentes. Infectio. 2013;17(1S). https:\/\/doi.org\/0.1016\/S0123-9392(13)70019-5","DOI":"10.1016\/S0123-9392(13)70019-5"},{"key":"99196","doi-asserted-by":"crossref","unstructured":"Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. \u03b1-blockers, antibiotics and antiinflammatories have a role in the management of chronic prostatitis\/chronic pelvic pain syndrome. BJU Int. 2012;110:1014-22. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11088.x","DOI":"10.1111\/j.1464-410X.2012.11088.x"},{"key":"99197","doi-asserted-by":"crossref","unstructured":"Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174:1914-20. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5214","DOI":"10.1001\/jamainternmed.2014.5214"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5103\/4475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5103\/4475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:21:48Z","timestamp":1594920108000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/5103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,15]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.5103","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"2020-06-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Original articles","name":"content_type","label":"Content Type"}]}}